<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04276883</url>
  </required_header>
  <id_info>
    <org_study_id>BXCL501-302</org_study_id>
    <nct_id>NCT04276883</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder</brief_title>
  <acronym>SERENITY II</acronym>
  <official_title>A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine Efficacy and Safety of BXCL501 In Agitation Associated With Bipolar Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioXcel Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cognitive Research Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>BioXcel Therapeutics Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a definitive study to support the safety and efficacy evaluation of BXCL501 for the&#xD;
      acute treatment of agitation in bipolar disorder. The BXCL501-302 study is designed to&#xD;
      characterize the efficacy, safety and tolerability of BXCL501 (sublingual film formulation of&#xD;
      DEX, HCl) in agitation associated with bipolar disorder.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will enroll approximately 375 subjects randomized 1:1:1 to dose regimens of 180µg,&#xD;
      120µg BXCL501, or placebo stratified by age &lt; 65 and age ≥ 65. Male and female adults with&#xD;
      acute agitation associated with bipolar disorder will be enrolled. Eligible subjects (acutely&#xD;
      agitated subjects with bipolar disorder, generally hypomanic, manic or mixed episodes) may be&#xD;
      identified in outpatient clinics, mental health, psychiatric or medical emergency services&#xD;
      including medical/psychiatric observation units, or as newly admitted to a hospital setting&#xD;
      for acute agitation or already in hospital for chronic underlying conditions. Subjects will&#xD;
      be domiciled in a clinical research setting or hospitalized to remain under medical&#xD;
      supervision while undergoing screening procedures to assess eligibility. Efficacy and safety&#xD;
      assessments will be conducted periodically before and after dosing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 24, 2020</start_date>
  <completion_date type="Actual">May 21, 2020</completion_date>
  <primary_completion_date type="Actual">May 21, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>phase III, randomized, double-blind, placebo-controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind, placebo-controlled</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Primary End Point</measure>
    <time_frame>120 minutes</time_frame>
    <description>Absolute change from baseline in the PEC score at 2 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Key Secondary Endpoint</measure>
    <time_frame>120 minutes</time_frame>
    <description>Earliest time where an effect on agitation is apparent as measured by change from baseline PEC total score in contrast with placebo</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">378</enrollment>
  <condition>Agitation Associated With Bipolar Disorder</condition>
  <condition>Agitation,Psychomotor</condition>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>120 Micrograms</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sublingual film containing 120 Micrograms Dexmedetomidine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>180 Micrograms</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sublingual film containing 180 Micrograms Dexmedetomidine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sublingual placebo film</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sublingual film containing Dexmedetomidine (BXCL501)</intervention_name>
    <description>Sublingual film containing Dexmedetomidine (BXCL501)</description>
    <arm_group_label>120 Micrograms</arm_group_label>
    <arm_group_label>180 Micrograms</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Film</intervention_name>
    <description>Placebo Film for BXCL501</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female patients between the ages of 18 to 75 years, inclusive.&#xD;
&#xD;
          2. Patients who have met DSM-5 criteria for bipolar I or II disorder.&#xD;
&#xD;
          3. Patients who are judged to be clinically agitated at Screening and Baseline with a&#xD;
             total score of ≥ 14 on the 5 items (poor impulse control, tension, hostility,&#xD;
             uncooperativeness, and excitement) comprising the PANSS Excited Component (PEC).&#xD;
&#xD;
          4. Patients who have a score of ≥ 4 on at least 1 of the 5 items on the PEC at Baseline.&#xD;
&#xD;
          5. Patients who read, understand and provide written informed consent.&#xD;
&#xD;
          6. Patients who are in good general health prior to study participation as determined by&#xD;
             a detailed medical history, physical examination, 12-lead ECG with rhythm strip, blood&#xD;
             chemistry profile, hematology, urinalysis, and in the opinion of the Principal&#xD;
             Investigator.&#xD;
&#xD;
          7. Participants who agree to use a medically acceptable and effective birth control&#xD;
             method&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with agitation caused by acute intoxication, including positive&#xD;
             identification of alcohol by breathalyzer or drugs of abuse (with the exception of&#xD;
             THC) during urine screening.&#xD;
&#xD;
          2. Use of benzodiazepines or other hypnotics or oral or short-acting intramuscular&#xD;
             antipsychotic drugs in the 4 hours before study treatment.&#xD;
&#xD;
          3. Treatment with alpha-1 noradrenergic blockers (terazosin, doxazosin, tamsulosin,&#xD;
             alfuzosin, or prazosin) or other prohibited medications.&#xD;
&#xD;
          4. Patients who are judged to be at significant risk of suicide.&#xD;
&#xD;
          5. Female patients who have a positive pregnancy test at screening or are breastfeeding.&#xD;
&#xD;
          6. Patients who have hydrocephalus, seizure disorder, or history of significant head&#xD;
             trauma, stroke, transient ischemic attack, subarachnoid bleeding, brain tumor,&#xD;
             encephalopathy, meningitis, Parkinson's disease or focal neurological findings.&#xD;
&#xD;
          7. History of syncope or other syncopal attacks, current evidence of hypovolemia,&#xD;
             orthostatic hypotension.&#xD;
&#xD;
          8. Patients with laboratory or ECG abnormalities considered clinically significant by the&#xD;
             investigator.&#xD;
&#xD;
          9. Patients with serious or unstable medical illnesses.&#xD;
&#xD;
         10. Patients who have received an investigational drug within 30 days prior to the current&#xD;
             agitation episode.&#xD;
&#xD;
         11. Patients who are considered by the investigator, for any reason, to be an unsuitable&#xD;
             candidate for receiving DEX.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>BioXcel Clinical Research Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BioXcel Clinical Research Site</name>
      <address>
        <city>Cerritos</city>
        <state>California</state>
        <zip>90703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BioXcel Clinical Research Site</name>
      <address>
        <city>Culver City</city>
        <state>California</state>
        <zip>90230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BioXcel Clinical Research Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BioXcel Clinical Research Site</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BioXcel Clinical Research Site</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BioXcel Clinical Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BioXcel Clinical Research Site</name>
      <address>
        <city>Gaithersburg</city>
        <state>Maryland</state>
        <zip>20877</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BioXcel Clinical Research Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BioXcel Clinical Research Site</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BioXcel Clinical Research Site</name>
      <address>
        <city>Marlton</city>
        <state>New Jersey</state>
        <zip>08053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BioXcel Clinical Research Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BioXcel Clinical Research Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78754</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BioXcel Clinical Research Site</name>
      <address>
        <city>DeSoto</city>
        <state>Texas</state>
        <zip>75115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BioXcel Clinical Research Site</name>
      <address>
        <city>Richardson</city>
        <state>Texas</state>
        <zip>75080</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 18, 2020</study_first_submitted>
  <study_first_submitted_qc>February 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2020</study_first_posted>
  <last_update_submitted>August 18, 2020</last_update_submitted>
  <last_update_submitted_qc>August 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psychomotor Agitation</mesh_term>
    <mesh_term>Disease</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

